No Data
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $26
Barclays analyst Balaji Prasad maintains $Organon & Co(OGN.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of 47.3% and a
Barclays Keeps Their Buy Rating on Organon (OGN)
Sector Update: Health Care Stocks Advance in Afternoon Trading
Evercore Initiates Organon & Co(OGN.US) With Buy Rating
Evercore analyst Umer Raffat initiates coverage on $Organon & Co(OGN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 49.0% and a total average return of -7.2%
Roivant Flips a Skin Drug to Organon -- Barrons.com
Express News | Organon Shares Down 1.3%